Table 2.
DNA methylation associated with T2D in the Islet T2D case-control cohort within genes differentially expressed in islets from T2D cases vs. controls that also associated with future T2D based on blood DNA methylation in the prospective EPIC-Potsdam T2D case-control study
| Islet T2D case-control cohort | EPIC-Potsdam | |||||||
|---|---|---|---|---|---|---|---|---|
| DNA methylation | RNA-seq | Blood DNA methylation | ||||||
| CpG site | Absolute difference | P-value | Odds ratio (95% CI) |
P-value | Gene | P-value | Odds ratio (95% CI) |
P-value |
| cg05324789 | −3.50% | 3.2 × 10−4 | 0.77 (0.65−0.90) | 0.0014 | NKX6.2 | 4.3 × 10−5 | 0.43 (0.24−0.76) | 0.004 |
| cg20355381 | −5.60% | 4.4 × 10−7 | 0.63 (0.47−0.78) | 3.1 × 10−4 | CABLES1 | 1.2 × 10−4 | 0.56 (0.37−0.84) | 0.006 |
| cg15167202 | −4.70% | 6.8 × 10−4 | 0.85 (0.76−0.94) | 0.0027 | SYNPO | 3.0 × 10−4 | 0.43 (0.20−0.94) | 0.034 |
| cg10339923 | −8.30% | 5.0 × 10−8 | 0.76 (0.66−0.86) | 4.9 × 10−5 | RHOT1 | 3.3 × 10−4 | 0.68 (0.47−0.97) | 0.035 |
For islet DNA methylation, both absolute difference (cases-controls) based on linear regression and odds ratios based on logistic regression are shown.